Share on StockTwits

Shares of Masimo Corp. (NASDAQ:MASI) have received an average rating of “Hold” from the seven ratings firms that are currently covering the stock, Analyst Ratings.Net reports. Four research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $28.00.

A number of research firms have recently commented on MASI. Analysts at BTIG Research initiated coverage on shares of Masimo Corp. in a research note on Tuesday. They set a “buy” rating and a $32.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Masimo Corp. in a research note on Friday, June 13th. They now have a $25.00 price target on the stock. Finally, analysts at Citigroup Inc. reiterated a “hold” rating on shares of Masimo Corp. in a research note on Friday, May 2nd. They now have a $29.00 price target on the stock.

Masimo Corp. (NASDAQ:MASI) traded up 0.96% during mid-day trading on Tuesday, hitting $24.18. The stock had a trading volume of 242,208 shares. Masimo Corp. has a 1-year low of $21.45 and a 1-year high of $32.20. The stock has a 50-day moving average of $23.98 and a 200-day moving average of $26.67. The company has a market cap of $1.372 billion and a price-to-earnings ratio of 21.18.

Masimo Corp. (NASDAQ:MASI) last released its earnings data on Wednesday, April 30th. The company reported $0.30 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.29 by $0.01. The company had revenue of $139.80 million for the quarter, compared to the consensus estimate of $144.01 million. During the same quarter in the prior year, the company posted $0.28 earnings per share. On average, analysts predict that Masimo Corp. will post $1.29 earnings per share for the current fiscal year.

Masimo Corporation is a global medical technology company that develops, manufactures, and markets noninvasive patient monitoring products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.